Systemic Inflammatory Response Syndrome Treatment Market Size, Share, Trends, Growth, Consumption, Production, Revenue and Forecast 2020 - 2027

The global systemic inflammatory response syndrome treatment market size was valued at US$ 9.5 Bn in 2019 and to reach valuation US$ 17.9 billion by 2027 with a CAGR of 8% from 2020 to 2027.

Systemic inflammatory response syndrome (SIRS) is defined as a clinical response to a nonspecific onslaught of either infectious or noninfectious origin. SIRS is nonspecific and can be caused by ischemia, inflammation, trauma, infection, or several indications combined. Infection is a major cause of systemic inflammatory response syndrome; however, a number of other indications, including trauma, ARDS, neoplasm, burn injury, pancreatitis, and dysfunctional macrophage activation are also recognized causes.

A Key Driver

• Systemic inflammatory response syndrome SIRS is one of the major criteria for determining post-surgical complications and end-organ dysfunction. Development of the syndrome is related to long hospital stay, high incidence of multiple organ dysfunction, and increased morbidity.
• SIRS is among the common post-operative complications in cardiac surgery, leading to organ dysfunction or even death. The prevalence of SIRS among pediatric patients is expected to increase in the near future. An article published by the University of Colorado School of Medicine stated that, out of 56,210 visitors to emergency departments during a 1-year study period, 40,356 pediatric patients met inclusion criteria. Among the included study population, patients with SIRS vital signs accounted for 92.8% of all the visits with fever >38.5°C.
• An article published by the U.S. National Library of Medicine National Institutes of Health indicated that, out of 372,844,465 visits to the emergency department from 2007 to 2010, an estimated 17.8% ED visitors had SIRS, i.e., 16.6 million adult ED visits with SIRS per year. This retrospective study was conducted as a part of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for four years. The study concluded that SIRS is quite common among visitors to the ED.
• An article published by the American Academy of Neurology stated that, of the 780 patients with ICH, 21.8% developed non-infectious SIRS and 37.3% developed sepsis during hospitalization.
• Therefore, steady rise in the prevalence of SIRS is likely to drive the global systemic inflammatory response syndrome treatment market during the forecast period.

In terms of indication, the others segment held a major share of the global systemic inflammatory response syndrome treatment market in 2019. The segment is anticipated to dominate the market during the forecast period, owing to increased penetration. Based on end user, the hospitals & ambulatory surgical centers segment is expected to account for a significant share of the global systemic inflammatory response syndrome treatment market. The segment is likely to grow at a rapid pace during the forecast period. The hospitals & ambulatory surgical centers segment is projected to dominate the global market during the forecast period, due to increase in inpatient admissions in hospitals and ambulatory surgical centers. However, limited availability of therapeutics for SIRS and lack of quality care for critically-ill patients are anticipated to hamper the growth of the global SIRS treatment market during the forecast period.

Prominent Regions

North America held a major share of the global systemic inflammatory response syndrome treatment market in 2019. The market in the region is expected to grow at a rapid pace during the forecast period. The market in North America is driven primarily by a rise in the prevalence of SIRS and increase in knowledge about SIRS among healthcare professionals. Additionally, surge in government initiatives toward infectious & non-infectious diseases, increase in the geriatric population that is at high risk, and a large number of players in North America focusing on R&D activities to introduce technologically-advanced systemic inflammatory response syndrome treatments with improved designs propel the market in the region. The systemic inflammatory response syndrome treatment market in Asia Pacific is likely to witness strong growth. Asia Pacific is a relatively untapped market as compared to developed regions. Hence, the region offers immense opportunities to market players. Rise in the prevalence of SIRS, increase in knowledge about SIRS among healthcare professionals, growth of the healthcare industry, and awareness in the region fuel the growth of the SIRS treatment market in the region.

Europe held the second-largest market share in 2019. Well-developed healthcare infrastructure augments the systemic inflammatory response syndrome treatment market in the region. The markets in the Middle East & Africa and Latin America are projected to witness moderate growth in the near future.

Prominent players operating in the global SIRS treatment market include -

• CytoSorbents Corporation
• RegeneRx Biopharmaceuticals, Inc.
• Endacea, Inc.
• Adrenomed AG
• GlaxoSmithKline plc
• Asahi Kasei Corporation
• Cardinal Health
• Smith & Nephew plc
• ConvaTec, Inc.
• AstraZeneca
• Orion Corporation
• CHIESI Farmaceutici S.p.A.
• Mylan N.V.

Market Segmentation

By Indication

• Meningitis
• Urinary Tract Infection (UTI)
• Pneumonia
• Hemorrhage
• Autoimmune Diseases
• Others

By End User

• Hospital & Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of LATAM
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Nordic
  • Benelux
  • Russia
  • Poland
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • Japan
  • ASEAN
  • Australia & New Zealand
  • Rest of APAC
• Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA 

This report on the systemic inflammatory response syndrome (SIRS) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period.

The report provides the overall revenue of the systemic inflammatory response syndrome treatment market for the period of 2017–2027, considering 2018 as the base year.

The report also provides the compound annual growth rate (CAGR) for the systemic inflammatory response syndrome treatment market for the forecast period.

The report has been prepared after an extensive research. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global SIRS treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approach to study various phenomena in the global systemic inflammatory response syndrome treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included.Additionally, the report sheds light on the changing competitive dynamics in the global systemic inflammatory response syndrome treatment market.

These indices serve as valuable tools for existing market players as well as for entities interested in entering the global systemic inflammatory response syndrome treatment market.

The report delves into the competitive landscape of the global systemic inflammatory response syndrome treatment market.Key players operating in the global SIRS treatment market are identified, and each one of these have been profiled for their distinguishing business attributes.

Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global systemic inflammatory response syndrome treatment market report.

Key Questions Answered in the Systemic inflammatory Response Syndrome Treatment Market Report

• What will be the Y-o-Y growth of the systemic inflammatory response syndrome treatment market between 2020 and 2027?
• What is the influence of the changing trends in technologies on the systemic inflammatory response syndrome treatment market?
• Will North America continue to be the most profitable market for systemic inflammatory response syndrome treatment providers?
• Which factors will hamper the growth of the global systemic inflammatory response syndrome treatment market during the forecast period?
• Which are the leading companies in the global systemic inflammatory response syndrome treatment market?
• What are the opportunities in the global systemic inflammatory response syndrome treatment market?

Research Methodology

A unique research methodology has been utilized by the analyst to conduct comprehensive research on the global systemic inflammatory response syndrome treatment market, and arrive at conclusions on the prospects of the market. This research methodology is a combination of primary and secondary researches, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global systemic inflammatory response syndrome treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers.

These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from systemic inflammatory response syndrome treatment market leaders.Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global systemic inflammatory response syndrome treatment market with accuracy.

The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching estimates on the future prospects of the global systemic inflammatory response syndrome treatment market more reliably and accurately.